MedPath

ifestyle and pharmacological regulation of lipoprotein metabolism in the metabolic syndrome

Conditions
Obesity
Type 2 diabetic mellitus
Dyslipidaemia
Diet and Nutrition - Obesity
Metabolic and Endocrine - Diabetes
Registration Number
ACTRN12606000152527
Lead Sponsor
niversity of Western Australia
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

BMI <40kg/m2 will be recruited. PM will be defined by: no menstrual cycle for 1 year and FSH >30U/L, or if the subject has had a hysterectomy or surgical sterilization. The MetS will be defined by the new International Diabetes Federation (IDF) criteria: central obesity (waist circumference >80cm for women and >94cm for men) plus triglycerides =1.7mmol/L, non-HDL-cholesterol >3.4mmol/L and insulin resistance (HOMA >2.2).Exclusion: Subjects with genetic hyperlipidemia, (eg FH), LDL-cholesterol >6.5mmol/L, proteinuria, hypothyroidism, alcoholism (>30g/day), creatinaemia (>130µmol/L), hepatic dysfunction (AST or ALT >3x ULN) and major systemic illness; pre-menopause women; use of steroids or other agents that may influence lipid metabolism, cardiovascular event within past 6 months, use of hypocaloric diets, anaemia; a history of intolerance to ezetimibe.

Exclusion Criteria

No exclusion criteria

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
High density lipoprotein (HDL)-apolipoprotein (apo) A-I and HDL-apoA-II production rates[Before and after 16 week intervention program];High density lipoprotein (HDL)-apolipoprotein (apo) A-I and HDL-apoA-II catabolic rates[Before and after 16 week intervention program]
Secondary Outcome Measures
NameTimeMethod
Apo B production and catabolic rates[Before and after 16 week intervention program.];Cholesterol absorption and synthesis[Before and after 16 week intervention program.]
© Copyright 2025. All Rights Reserved by MedPath